Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...